A bit of good news-ish.
practiceupdate.com/C/79098/...
OBJECTIVES
To study if androgen deprivation therapy (ADT), the mainstay treatment for advanced and disseminated prostate cancer, is associated with risk of dementia.
METHODS
Risk of dementia in men with prostate cancer primarily managed with ADT or watchful waiting (WW) in Prostate Cancer data Base Sweden (PCBaSe) was compared with that of prostate cancer-free men, matched on birth year and county of residency. We used Cox's regression to calculate hazard ratios for Alzheimer's and non-Alzheimer's dementia (vascular dementia, dementia secondary to other diseases or unspecified dementias) for different types and duration of ADT and oral antiandrogens as well as for men managed with watchful waiting.
RESULTS
25 967 men with prostate cancer and 121 018 prostate cancer-free men were followed for a median time of four years, and in both groups 6% of the men were diagnosed with dementia. Use of Gonadotropin-releasing hormone agonists (GnRH agonists, Hazard Ratio (HR): 1.15 (95%CI: 1.07-1.23) and orchiectomy, HR 1.60 (95%CI: 1.32-1.93) were associated with an increased risk of dementia, as compared to prostate cancer-free men. However, this increase in risk was only observed for non-Alzheimer's dementia and occurred from year one to four after start of ADT. No increase in for any type of dementia was observed for men treated with antiandrogens or for men on WW.
CONCLUSION
This population-based cohort study does not support previous observations of an increased risk of Alzheimer's dementia for men on ADT. However, there was a small increase in risk of non-Alzheimer's dementia.